去纤维钠（去纤苷）副作用及处理

(Defitelio) is a polydisperse mixture of single-stranded oligonucleotides that can prevent endothelial cell damage without increasing the risk of systemic bleeding, and protect liver sinusoidal endothelial cells without weakening the anti-tumor effect of cytotoxic drugs. Although the efficacy of this drug has been confirmed by clinical trials, patients may still experience some side effects during actual use. How to take effective measures to deal with it has become an important issue that patients currently face.

Some foreign researchers have evaluated the safety of defibrinated sodium based on the current clinical research results on defibrinated sodium. The results show that compared with other anticoagulant and antithrombotic drugs used to prevent and treat HVOD after HSCT, most clinical study results show that DF is safe and tolerable.

Common adverse reactions related to defibrotide sodium (defibrinoside) include bleeding, hypotension, gastrointestinal discomfort (such as nausea, vomiting, abdominal discomfort), and occasional injection site adverse reactions, but most are mild to moderate. Adverse reactions of grade III or above are occasionally seen, such as sepsis, pulmonary edema, cytomegalovirus infection, hypotension, respiratory failure and alveolar hemorrhage. The causal relationship between defibrinated sodium and these adverse reactions cannot be determined.

The incidence of adverse reactions of defibrotide sodium (defibrinoside) is highest when used to treat sHVOD patients and lowest when used for prophylaxis, indicating that early application of defibrotide sodium can reduce the incidence of adverse reactions. The condition of HVOD patients is often more severe and often complicated by MOF, GVHD and infection. When conducting safety analysis of defibrination sodium, it is difficult to determine the clear cause-and-effect relationship between defibrination and the occurrence of adverse reactions in patients. Compared with historical controls, there was no statistically significant difference in the incidence of adverse reactions in patients, indicating that adverse reactions when using defibrinated sodium may be related to the patient's disease itself.

In order to reduce the damage caused by the side effects of medication as much as possible, targeted measures need to be taken during treatment.

Recommended hot articles: /newsDetail/78630.html